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Editorial
The host’s angiotensin-converting enzyme polymorphism may explain epidemiological findings
in COVID-19 infections
The outbreak of the COVID-19 pandemia in 2019/2020 has stimu-
lated research on clinical laboratory findings in this condition, as evi-
denced by two recent papers in this journal [1,2]. We know that an-
giotensin-converting enzyme is involved in corona virus infection.
Pathogenic corona viruses (severe acute respiratory syndrome corona
virus [SARS-CoV] and SARS-CoV-2) bind to their target cells through
angiotensin-converting enzyme 2 (ACE2), [3,4]. Not only has ACE2
facilitated the invasion of SARS virus for rapid replication, but also
ACE2 is depleted from the cell membrane and therefore the damaging
effects of Ang II are enhanced, resulting in acute deterioration of lung
tissues [5]. The angiotensin-converting 1 (ACE1) enzyme is character-
ized by a genetic deletion/insertion (D/I) polymorphism in intron 16,
which is associated with alterations in circulating and tissue con-
centrations of ACE. The D allele is associated with a reduced expression
of ACE2. Although ACE2 and ACE share only 42% of amino acid
identity, they both act as carboxypeptidases to cleave amino acids from
the peptides’ carboxyl terminal [6].
As this D/I polymorphism shows an important geographical varia-
tion [7], we postulated that the variability in D/I genotype distribution
might partly explain the variable prevalence of the COVID-19 infection
amongst continental European countries. Therefore, we compared the
D-allele frequency of the ACE1 gene as obtained in 25 different Eur-
opean countries with the prevalence and mortality of COVID-19, as
calculated on March 20, 2020 by Johns Hopkins [8]. Fig. 1 shows the
regression data. Data from Austria, Belgium, Croatia, Czech Republic,
Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel,
Italy, Lithuania, Moldova, the Netherlands, Poland, Portugal, Romania,
Slovakia, Slovenia, Spain, Sweden, Switzerland, and Turkey were in-
cluded in the analysis. The log transformed prevalence of COVID-19
infections inversely correlates with the ACE D allele frequency: log
(prevalence; number of cases/106 inhabitants) = 6.358–0.079 (D-allele
frequency, %), r2 = 0.378; p = 0.001. About 38% of the variability of
the prevalence can be explained by the relative frequency of the ACE1
D-allele. Similarly, a significant correlation could be noted between
COVID-19 caused mortality (Spearman r = −0.510, p = 0.01) and the
prevalence of the ACE1 D-allele. It should also be noted that the two
Asian countries which were initially severely hit by the virus, China and
Korea, are also characterized by low D allele frequencies.
These data suggest that ACE1 D/I polymorphism may be regarded
as a confounder in the spread of COVID-19 and the outcome of the
infection in various European populations. These findings are in
agreement with the role of ACE in pulmonary infections caused by
corona viruses [4]. The ACE D/I genotype may affect the clinical course
of the infection.
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Fig. 1. Prevalence of COVID 19 in 25 European countries (on March 20, 2020 vs. ACE1 D-allele frequency (%): log (prevalence; no. of cases/106 in-
habitants) = 6.358–0.079 (D-allele frequency, %), r2 = 0.378; p = 0.001.
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